# MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)

> **NCT01643850** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 36 (actual)

## Conditions studied

- Pigmented Villonodular Synovitis
- PVNS
- Giant Cell Tumor of the Tendon Sheath
- GCCTS
- Tenosynovial Giant Cell Tumor Localized or Diffused Type
- GCTS

## Interventions

- **DRUG:** MCS110
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01643850
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04-23
- **Primary completion:** 2017-12-07
- **Final completion:** 2018-12-21
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01643850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01643850, "MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01643850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*